IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
Con tacts (Pharm): Chair man: Philippe
Besnard; Com mer cial Op er a tions: Karl Parance;
Re search & De vel op ment: Pascal Albert
Sub sid iary of: Sandoz, Ger many (100%)
NOVARTIS
Full Name: Novartis Pharma S.A.S.
Postal Ad dress: BP 356, 92 506
Rueil-Malmaison Cedex
Street Ad dress: 2 et 4 rue Lionel Terray, 92 506
Rueil-Malmaison Cedex
Tel: +33 1 55 47 60 00
Fax: +33 1 55 47 60 50
Home Page: www.novartis.fr
De scrip tion: De vel oper, man u fac turer, for mu la -
tor, packager/as sem bler, im porter, ex porter, for -
mu la tor, dis trib u tor, pro moter, sales/detailer.
De vel ops, man u fac tures, pro motes for other
com pa nies. Prod uct ranges in clude: phar ma ceu ti -
cal prod ucts (branded, unbranded, pre scrip tion,
non-pre scrip tion), hos pi tal pharmaceuticals, oph -
thal mic prod ucts, bi o log i cal prod ucts, bio tech nol -
ogy prod ucts. Es tab lished 1997. 2002
phar ma ceu ti cal em ploy ees in 2007. Di vi sions in -
clude: Novartis Oncologie; Novartis Immunologie
& Transplantation; Novartis Ophthalmics; General
Medicine.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 501-1,000 (2007)
Con tacts (Pharm): Chair man: Jean Christphe
Tellier; Man u fac ture: Serge Runser; Re search &
De vel op ment: Pat rick Trunet; Gen eral Con tact:
Hugues Joublin
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 1,600-1,700 mil -
lion
Prod ucts (% of Sales by Lead ing 5): 45-50%
Ther a peu tic Classes (% of Sales by Lead ing
5): 60-65%
Dose Forms (% of Sales by Lead ing 5):
90-95%
Prin ci pal Prod ucts:
GLIVEC (antineoplastic other)
LUCENTIS (oc u lar antineovascularization prod -
uct)
COTAREG (an gio ten sin-II an tag o nist com bi na -
tion)
TAREG (an gio ten sin-II an tag o nist plain)
FEMARA (cytostatic hor mone an tag o nist)
Ther a peu tic Range:
renin-an gio ten sin sys tem agents 19%
antineoplastics 15%
ophthalmologicals 15%
antiasthma and COPD prod ucts 8%
immunosuppressive agents 6%
Lead ing Dose Forms:
coated tab lets 48%
vi als 18%
cap sules 18%
tab lets 6%
in fu sions 5%
NOVARTIS CON SUMER HEALTH
Full Name: Novartis Sante Familiale S.A.S.
Postal Ad dress: BP 440, 92 845
Rueil-Malmaison Cedex
Street Ad dress: 14, Bou le vard Richelieu, 92 500
Rueil-Malmaison Cedex
Tel: +33 1 55 47 80 00
Fax: +33 1 55 47 80 20
Home Page: www.novartis.fr
De scrip tion: Re searcher, de vel oper, man u fac -
turer, for mu la tor, packager/as sem bler, im porter,
ex porter, dis trib u tor, pro moter, sales/detailer.
Pro motes for other com pa nies. Prod uct ranges in -
clude: phar ma ceu ti cal prod ucts (branded, pre -
scrip tion, non-pre scrip tion), hos pi tal
pharmaceuticals. Established 1997.
Con tacts (Pharm): Chair man: San ti ago Teruel;
Com mer cial Op er a tions: Marc Thibiant; Man u fac -
ture: Nicolas Manceau; Mar ket Re search: Bruno
Geffroy; Re search & De vel op ment: Jacques
Uhlrich; Gen eral Con tact: Marc Thibiant
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 100-110 mil lion
Prod ucts (% of Sales by Lead ing 5): 65-70%
Ther a peu tic Classes (% of Sales by Lead ing
5): 85-90%
Dose Forms (% of Sales by Lead ing 5):
80-85%
Prin ci pal Prod ucts:
VOLTARENE EMULGEL (antirheumatic top i cal)
NICOTINELL TTS (antismoking prod uct)
ZYMADUO (vi ta min A/D plain/com bi na tion)
IMPORTAL (lax a tive)
LAMISIL CREME (dermatological antifungal)
Ther a peu tic Range:
anti rheu ma tics top i cal 41%
CNS drugs other 13%
vi ta mins 11%
lax a tives 10%
dermatological antifungals 10%
Lead ing Dose Forms:
pres sur ised aero sols 25%
© 2009 IMS Health In cor po rated or its af fil i ates Page 169